Telomere dysfunction and activation of alternative lengthening of telomeres in B-lymphocytes infected by Epstein-Barr virus

Oncogene

Volumn 32, Issue 49, 2013, Pages 5222-5230

  Kamranvar, S A ^a   Chen, X ^a   Masucci, M G ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

ALT; EBV; shelterin; telomerase; telomere; TRF2

Indexed keywords

ARTICLE; B LYMPHOCYTE; CELL ACTIVATION; CELL HETEROGENEITY; CELL IMMORTALIZATION; CELL NUCLEUS INCLUSION BODY; CELL PROLIFERATION; CELL PROTECTION; ENZYME ACTIVITY; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOBLASTOID CELL LINE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SISTER CHROMATID; SISTER CHROMATID EXCHANGE; TELOMERE; TELOMERE HOMEOSTASIS; ENZYME ACTIVATION; GENETICS; HUMAN; METABOLISM; VIROLOGY;

HUMAN HERPESVIRUS 4;

ATRX PROTEIN, HUMAN; DNA HELICASE; NUCLEAR PROTEIN; POT1 PROTEIN, HUMAN; TELOMERASE; TELOMERE BINDING PROTEIN; TELOMERIC REPEAT BINDING FACTOR 1; TELOMERIC REPEAT BINDING FACTOR 2; TERF2 PROTEIN, HUMAN;

B-LYMPHOCYTES; DNA HELICASES; ENZYME ACTIVATION; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; NUCLEAR PROTEINS; SISTER CHROMATID EXCHANGE; TELOMERASE; TELOMERE; TELOMERE HOMEOSTASIS; TELOMERE-BINDING PROTEINS; TELOMERIC REPEAT BINDING PROTEIN 1; TELOMERIC REPEAT BINDING PROTEIN 2;

EID: 84893480950     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.189     Document Type: Article

References (63)

1. Blackburn EH. Structure and function of telomeres. Nature 1991; 350: 569-573.
2. de Lange T, Shiue L, Myers RM, Cox DR, Naylor SL, Killery AM et al. Structure and variability of human chromosome ends. Mol Cell Biol 1990; 10: 518-527.
3. Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, Moss H et al. Mammalian telomeres end in a large duplex loop. Cell 1999; 97: 503-514.
4. Makarov VL, Hirose Y, Langmore JP. Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening. Cell 1997; 88: 657-666.
5. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev 2005; 19: 2100-2110.
6. Palm W, de Lange T. How shelterin protects mammalian telomeres. Annu Rev Genet 2008; 42: 301-334.
7. O'Connor MS, Safari A, Xin H, Liu D, Songyang Z. A critical role for TPP1 and TIN2 interaction in high-order telomeric complex assembly. Proc Natl Acad Sci USA 2006; 103: 11874-11879.
8. Walker JR, Zhu XD. Post-translational modifications of TRF1 and TRF2 and their roles in telomere maintenance. Mech Ageing Dev 2012; 133: 421-434.
9. van Steensel B, de Lange T. Control of telomere length by the human telomeric protein TRF1. Nature 1997; 385: 740-743.
10. Denchi EL, de Lange T. Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1. Nature 2007; 448: 1068-1071.
11. van Steensel B, Smogorzewska A, de Lange T. TRF2 protects human telomeres from end-to-end fusions. Cell 1998; 92: 401-413.
12. Karlseder J, Broccoli D, Dai Y, Hardy S, de Lange T. p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science 1999; 283: 1321-1325.
13. Hockemeyer D, Sfeir AJ, Shay JW, Wright WE, de Lange T. POT1 protects telomeres from a transient DNA damage response and determines how human chromosomes end. EMBO J 2005; 24: 2667-2678.
14. Kim SH, Beausejour C, Davalos AR, Kaminker P, Heo SJ, Campisi J. TIN2 mediates functions of TRF2 at human telomeres. J Biol Chem 2004; 279: 43799-43804.
15. Shay JW, Pereira-Smith OM, Wright WE. A role for both RB and p53 in the regulation of human cellular senescence. Exp Cell Res 1991; 196: 33-39.
16. Takai H, Smogorzewska A, de Lange T. DNA damage foci at dysfunctional telomeres. Curr Biol 2003; 13: 1549-1556.
17. Karlseder J, Smogorzewska A, de Lange T. Senescence induced by altered telomere state, not telomere loss. Science 2002; 295: 2446-2449.
18. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33: 787-791.
19. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 1995; 14: 4240-4248.
20. Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 1997; 3: 1271-1274.
21. Dunham MA, Neumann AA, Fasching CL, Reddel RR. Telomere maintenance by recombination in human cells. Nat Genet 2000; 26: 447-450.
22. Yeager TR, Neumann AA, Englezou A, Huschtscha LI, Noble JR, Reddel RR. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res 1999; 59: 4175-4179.
23. Bechter OE, Zou Y, Shay JW, Wright WE. Homologous recombination in human telomerase-positive and ALT cells occurs with the same frequency. EMBO Rep 2003; 4: 1138-1143.
24. Celli GB, Denchi EL, de Lange T. Ku70 stimulates fusion of dysfunctional telomeres yet protects chromosome ends from homologous recombination. Nat Cell Biol 2006; 8: 885-890.
25. Sfeir A, Kabir S, van Overbeek M, Celli GB, de Lange T. Loss of Rap1 induces telomere recombination in the absence of NHEJ or a DNA damage signal. Science 2010; 327: 1657-1661.
26. Wang RC, Smogorzewska A, de Lange T. Homologous recombination generates T-loop-sized deletions at human telomeres. Cell 2004; 119: 355-368.
27. Lovejoy CA, Li W, Reisenweber S, Thongthip S, Bruno J, de Lange T et al. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet 2012; 8: e1002772.
28. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004; 4: 757-768.
29. Xia T, O'Hara A, Araujo I, Barreto J, Carvalho E, Sapucaia JB et al. EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3. Cancer Res 2008; 68: 1436-1442.
30. Young LS, Murray PG. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene 2003; 22: 5108-5121.
31. Purtilo DT, Strobach RS, Okano M, Davis Jr. Epstein-Barr virus-Associated lymphoproliferative disorders. Lab Invest 1992; 67: 5-23.
32. Bird AG, McLachlan SM, Britton S. Cyclosporin A promotes spontaneous outgrowth in vitro of Epstein-Barr virus-induced B-cell lines. Nature 1981; 289: 300-301.
33. Mei YP, Zhu XF, Zhou JM, Huang H, Deng R, Zeng YX. siRNA targeting LMP1- induced apoptosis in EBV-positive lymphoma cells is associated with inhibition of telomerase activity and expression. Cancer Lett 2006; 232: 189-198.
34. Terrin L, Dal Col J, Rampazzo E, Zancai P, Pedrotti M, Ammirabile G et al. Latent membrane protein 1 of Epstein-Barr virus activates the hTERT promoter and enhances telomerase activity in B lymphocytes. J Virol 2008; 82: 10175-10187.
35. Yang J, Deng X, Deng L, Gu H, Fan W, Cao Y. Telomerase activation by Epstein-Barr virus latent membrane protein 1 is associated with c-Myc expression in human nasopharyngeal epithelial cells. J Exp Clin Cancer Res 2004; 23: 495-506.
36. Chen F, Liu C, Lindvall C, Xu D, Ernberg I. Epstein-Barr virus latent membrane 2A (LMP2A) down-regulates telomerase reverse transcriptase (hTERT) in epithelial cell lines. Int J Cancer 2005; 113: 284-289.
37. Sugimoto M, Tahara H, Ide T, Furuichi Y. Steps involved in immortalization and tumorigenesis in human B-lymphoblastoid cell lines transformed by Epstein-Barr virus. Cancer Res 2004; 64: 3361-3364.
38. Lacoste S, Wiechec E, Dos Santos Silva AG, Guffei A, Williams G, Lowbeer M et al. Chromosomal rearrangements after ex vivo Epstein-Barr virus (EBV) infection of human B cells. Oncogene 2010; 29: 503-515.
39. Sugimoto M, Ide T, Goto M, Furuichi Y. Reconsideration of senescence, immortalization and telomere maintenance of Epstein-Barr virus-transformed human B-lymphoblastoid cell lines. Mech Ageing Dev 1999; 107: 51-60.
40. Ford LP, Zou Y, Pongracz K, Gryaznov SM, Shay JW, Wright WE. Telomerase can inhibit the recombination-based pathway of telomere maintenance in human cells. J Biol Chem 2001; 276: 32198-32203.
41. Henson JD, Reddel RR. Assaying and investigating alternative lengthening of telomeres activity in human cells and cancers. FEBS Lett 2010; 584: 3800-3811.
42. Chung I, Osterwald S, Deeg KI, Rippe K. PML body meets telomere: the beginning of an ALTernate ending? Nucleus 2012; 3: 263-275.
43. Nikitin PA, Yan CM, Forte E, Bocedi A, Tourigny JP, White RE et al. An ATM/Chk2- mediated DNA damage-responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells. Cell Host Microbe 2010; 8: 510-522.
44. Martinez P, Blasco MA. Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. Nat Rev Cancer 2011; 11: 161-176.
45. Bellon M, Nicot C. Regulation of telomerase and telomeres: human tumor viruses take control. J Natl Cancer Inst 2008; 100: 98-108.
46. Henson JD, Cao Y, Huschtscha LI, Chang AC, Au AY, Pickett HA et al. DNA C-circles are specific and quantifiable markers of alternative-lengthening-of- telomeres activity. Nat Biotechnol 2009; 27: 1181-1185.
47. Cerone MA, Londono-Vallejo JA, Bacchetti S. Telomere maintenance by telomerase and by recombination can coexist in human cells. Hum Mol Gen 2001; 10: 1945-1952.
48. Hu J, Hwang SS, Liesa M, Gan B, Sahin E, Jaskelioff M et al. Antitelomerase therapy provokes ALT and mitochondrial adaptive mechanisms in cancer. Cell 2012; 148: 651-663.
49. Kataoka H, Tahara H, Watanabe T, Sugawara M, Ide T, Goto M et al. Immortalization of immunologically committed Epstein-Barr virus-transformed human B-lymphoblastoid cell lines accompanied by a strong telomerase activity. Differentiation 1997; 62: 203-211.
50. Royle NJ, Foxon J, Jeyapalan JN, Mendez-Bermudez A, Novo CL, Williams J et al. Telomere length maintenance-An ALTernative mechanism. Cytogen Gen Res 2008; 122: 281-291.
51. Cesare AJ, Reddel RR. Alternative lengthening of telomeres: models, mechanisms and implications. Nat Rev Genet 2010; 11: 319-330.
52. He H, Multani AS, Cosme-Blanco W, Tahara H, Ma J, Pathak S et al. POT1b protects telomeres from end-to-end chromosomal fusions and aberrant homologous recombination. EMBO J 2006; 25: 5180-5190.
53. De La Fuente R, Baumann C, Viveiros MM. Role of ATRX in chromatin structure and function: implications for chromosome instability and human disease. Reproduction 2011; 142: 221-234.
54. Azzalin CM, Reichenbach P, Khoriauli L, Giulotto E, Lingner J. Telomeric repeat containing RNA and RNA surveillance factors at mammalian chromosome ends. Science 2007; 318: 798-801.
55. Ritchie K, Seah C, Moulin J, Isaac C, Dick F, Berube NG. Loss of ATRX leads to chromosome cohesion and congression defects. J Cell Biol 2008; 180: 315-324.
56. Gruhne B, Sompallae R, Marescotti D, Kamranvar SA, Gastaldello S, Masucci MG. The Epstein-Barr virus nuclear antigen-1 promotes genomic instability via induction of reactive oxygen species. Proc Natl Acad Sci USA 2009; 106: 2313-2318.
57. von Zglinicki T. Role of oxidative stress in telomere length regulation and replicative senescence. Ann N Y Acad Sci 2000; 908: 99-110.
58. Opresko PL, Fan J, Danzy S, Wilson 3rd DM, Bohr VA. Oxidative damage in telomeric DNA disrupts recognition by TRF1 and TRF2. Nucleic Acids Res 2005; 33: 1230-1239.
59. Kamranvar SA, Gruhne B, Szeles A, Masucci MG. Epstein-Barr virus promotes genomic instability in Burkitt's lymphoma. Oncogene 2007; 26: 5115-5123.
60. Miller G, Shope T, Lisco H, Stitt D, Lipman M. Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes. Proc Natl Acad Sci USA 1972; 69: 383-387.
61. Lenoir GM, Vuillaume M, Bonnardel C. The use of lymphomatous and lymphoblastoid cell lines in the study of Burkitt's lymphoma. IARC Sci Publ 1985; 60: 308-318.
62. Torsteinsdottir S, Cuomo L, Klein E, Masucci MG. Stimulation with allogeneic Epstein-Barr virus-transformed lymphoblastoid cell lines generates HLA class I-specific CTLs with different target cell avidity. Cell Immunol 1991; 137: 501-513.
63. Parish CR, Glidden MH, Quah BJ, Warren HS. Use of the intracellular fluorescent dye CFSE to monitor lymphocyte migration and proliferation. Current Prot Immunol 2009; 84: 4.9.1-4.9.13.